MaxCyte agreed to buy Arcline-backed Akron Bio for $151.8 million in a deal that would add recurring sales of cell-therapy manufacturing materials to its cell-engineering business. The Nasdaq-listed buyer announced the agreement on November 10 and expects it to nearly double its revenue base.

Akron supplies therapy developers with materials used to grow and preserve cells, including growth factors, plasma-derived products and culture media. MaxCyte says these materials become part of customers’ validated manufacturing processes and regulatory filings, connecting the supplier to medicines from clinical development through commercial production.

The buyer forecasts about $28 million of Akron revenue and $7 million to $8 million of EBITDA in 2026, with positive cash flow. It expects the combination to bring annual cash burn below $10 million in 2027.

Arcline bought a majority interest in Akron in September 2019. Under the new agreement, sellers would receive $105 million in cash at closing, subject to adjustments, approximately 20.6 million MaxCyte shares valued at about $26.8 million using the November 9 share price, and $20 million in guaranteed deferred payments. The deferred cash falls due in two equal installments in January 2028 and January 2029.

MaxCyte also obtained a MidCap Financial commitment for up to $75 million of credit and expects to borrow $22 million when the acquisition closes. Its quarterly filing says final loan terms still require definitive documentation, and access to the full facility depends on borrowing conditions.

The acquisition is expected to close before the end of 2026, subject to customary conditions, without a financing or MaxCyte shareholder-approval requirement. Shares issued to the sellers would be locked up for six months after closing.

MaxCyte plans to use its existing sales operation to sell Akron’s products. Its quarterly filing cautions that few of Akron’s customers currently buy from MaxCyte and that the anticipated cross-selling may not materialize.

Sources
1MaxCyte’s Akron Bio acquisition announcement ↗
2MaxCyte Form 8-K ↗
3MaxCyte third-quarter 2026 Form 10-Q ↗
4Akron Bio’s acquisition announcement ↗
5Arcline’s September 2019 majority investment ↗